Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dose-ranging study

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    515 result(s) found for: Dose-ranging study. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-004623-19 Sponsor Protocol Number: BT0720-201-INT Start Date*: 2006-03-13
    Sponsor Name:Barrier Therapeutics, Inc.
    Full Title: A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis
    Medical condition: Treatment of Plaque Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003318-42 Sponsor Protocol Number: TAK-954-2004 Start Date*: 2019-06-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postope...
    Medical condition: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postope...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10076042 Feeding intolerance PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002315-41 Sponsor Protocol Number: RDEA806-501 Start Date*: 2008-08-13
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects with Symptomatic Gout
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000374-31 Sponsor Protocol Number: SB-683699/003 Start Date*: 2004-06-09
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in ...
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005025-37 Sponsor Protocol Number: RD.03.SPR.114322 Start Date*: 2017-08-30
    Sponsor Name:GALDERMA R&D, SNC
    Full Title: A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis su...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10014184 Eczema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002796-35 Sponsor Protocol Number: C4491011 Start Date*: 2021-01-07
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan...
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000254-23 Sponsor Protocol Number: ATL 962/175/CL Start Date*: 2004-11-09
    Sponsor Name:Alizyme Therapeutics Limited
    Full Title: A Phase II Multicentre, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of ATL 962 to Assess Weight Loss, Safety and Tolerability in Obese Patients with Type II Diabetes being ...
    Medical condition: Treatment of obesity in patients with Type II diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005075-88 Sponsor Protocol Number: V110_08 Start Date*: 2014-12-15
    Sponsor Name:Novartis Pharma K.K
    Full Title: A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1...
    Medical condition: Prophylaxis of A (H1N1) 2009 Swine Origin Pandemic Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-013037-19 Sponsor Protocol Number: VB-201-006-A Start Date*: 2010-02-08
    Sponsor Name:Vascular Biogenics Ltd.
    Full Title: A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001131-30 Sponsor Protocol Number: EZ-2053-001 Start Date*: 2005-07-22
    Sponsor Name:Fresenius Biotech North America
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter, Dose-ranging Study of an Anti-T-lymphocyte Immunglobuline (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of...
    Medical condition: Patients with end-stage pulmonary failure, who are receiving a primary single or double pulmonary allograft
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021414-32 Sponsor Protocol Number: A9541004 Start Date*: 2010-11-23
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    Full Title: A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE
    Medical condition: ISCHEMIC STROKE
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002738-36 Sponsor Protocol Number: AKST4290-205 Start Date*: 2019-10-30
    Sponsor Name:Alkahest, Inc.
    Full Title: A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular ...
    Medical condition: Newly Diagnosed Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004753-95 Sponsor Protocol Number: DBTY 000/Capsulin/1Mar Start Date*: 2006-03-27
    Sponsor Name:Diabetology Ltd
    Full Title: A Phase II, Dose Ranging Single Centre, Single Blind, Parallel-group, Controlled Study of the Safety, Tolerability and Effects on Metabolic Control of an Oral Insulin Formulation in a Type II Diabe...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001997-52 Sponsor Protocol Number: 20170755 Start Date*: 2018-12-28
    Sponsor Name:Amgen Inc
    Full Title: A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004475-36 Sponsor Protocol Number: DC-002 Start Date*: 2012-05-19
    Sponsor Name:Delta Crystallon B.V.
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patient...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002820-32 Sponsor Protocol Number: 250508BS Start Date*: 2005-12-08
    Sponsor Name:Dow Pharmaceutical Sciences Inc.
    Full Title: A Multi-Center, Double-Blind, Randomized, Dose-Ranging Study of the Safety and Efficacy of IDP-102 Gel 5 %, and 15 % Compared with Vehicle in the Treatment of Common Warts.
    Medical condition: common warts
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005606-23 Sponsor Protocol Number: 0594-003 Start Date*: 2006-03-24
    Sponsor Name:Merck Sharp and Dohme de España
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder Estudio multicéntrico, doble ciego, aleato...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000761-37 Sponsor Protocol Number: A3051073 Start Date*: 2018-03-23
    Sponsor Name:Pfizer, Inc.
    Full Title: A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Ado...
    Medical condition: NICOTINE DEPENDENCE
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057852 Nicotine dependence PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004384-48 Sponsor Protocol Number: 1311.2 Start Date*: 2013-12-13
    Sponsor Name:Boehringer Ingelheim
    Full Title: A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002354-12 Sponsor Protocol Number: CMBG453X2101 Start Date*: 2016-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 19:43:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA